Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02168777 · ClinicalTrials.gov registry record · Phase 1
Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer
A Phase 1 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02168777 is a Phase 1 study that was terminated before completion, run by Bayer. The registered enrollment target is 20 participants.
The verdict
NCT02168777, a Phase 1 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Phase I: Determine the maximum tolerated dose of combination of Regorafenib with Refametinib through a dose escalation study, all tumor types that meet certain inclusion/exclusion criteria can be entered. After the recommended dose is determined, the Phase II portion of the study will evaluate tolerability and efficacy of the combination treatment in patients with breast cancer, lung cancer, or colorectal cancer, respectively.
Interventions
- DRUG Refametinib (BAY86-9766)
- DRUG Regorafenib (Stivarga, BAY73-4506)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2014-06-23 |
| Est. Completion | 2016-04-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02168777
The ClinicalTrials.gov registry entry for NCT02168777 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Refametinib (BAY86-9766) is the first listed.
NCT02168777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02168777 about?
NCT02168777 is a clinical study titled "Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer". Phase I: Determine the maximum tolerated dose of combination of Regorafenib with Refametinib through a dose escalation study, all tumor types that meet certain inclusion/exclusion criteria can be entered. After the recommended dose is determined, the Phase II portion of the study will evaluate tole...
What is the current status of trial NCT02168777?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2014-06-23. Estimated completion is 2016-04-05.
What interventions are being tested in trial NCT02168777?
The interventions under investigation include: Refametinib (BAY86-9766) (DRUG), Regorafenib (Stivarga, BAY73-4506) (DRUG).
Who is sponsoring clinical trial NCT02168777?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.